ADC and XDC Specialist Services: From Synthesis to Signal

Ardena performs precise and scalable conjugation of antibodies, proteins, peptides, and polymer systems with highly potent payloads under GMP conditions. We support single and dual-payload constructs, including cytotoxic payloads and oligonucleotide payloads (AOCs). 

Technical highlights:

• Proven experience in antibody, polypeptide, polymer and nanoparticle conjugation
• Process optimisation to control drug-to-antibody ratio (DAR), conjugation heterogeneity, yield and robustness 
• Tangential flow filtration (TFF) and chromatographic purification for removal of free payloads and catalysts
• Scalable processes supporting volumes from laboratory to pilot production
• GMP compliant synthesis and analytical release testing

Ardena’s comprehensive bioanalytical service includes quantification of all ADC molecular entities, immunogenicity and associated biomarkers.

Ardena’s analytical labs are fully GLP compliant, supporting preclinical and clinical trials, helping you navigate through all stages of development. 

Core competencies include:

• Pharmacokinetics of total antibody, ADC, conjugated and free payload
• Immunogenicity
• Biomarker analyses: soluble, cellular and genomic biomarkers
• Expertise in multiple modalities

ADCs represent only one segment of a rapidly evolving conjugate field. Building on our expertise in linker and payload chemistry, bioconjugation and bioanalysis, Ardena supports developers advancing next-generation XDC platforms. 

Our experience extends to emerging conjugate formats, including: oligonucleotide conjugates, polymer-drug conjugates, nanoparticle-drug conjugates and Immune Stimulating Antibody Conjugates (ISACs).

By combining our strengths in drug linker chemistry, nanomedicine formulation, and bioconjugation, we enable the development of next generation targeted therapies.